Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avandia rosiglitazone regulatory update

FDA and GSK plan to supplement the existing boxed warning on the label of Avandia rosiglitazone to include new language noting that it has been associated with a potential increase in the risk of

Read the full 343 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE